StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $0.82 | $0.81 | -1.33% | 0.0M |
| 05-12 | $0.82 | $0.89 | +8.50% | 0.1M |
| 05-13 | $0.89 | $0.83 | -6.56% | 0.0M |
| 05-14 | $0.83 | $0.77 | -7.07% | 0.1M |
| 05-15 | $0.83 | $0.76 | -8.64% | 0.0M |
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
No sell-side coverage available for VTAK.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Metric | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 | Q1 2025 2025-03-31 |
|---|---|---|---|---|
Revenue | $819.00K | $581.00K | $355.00K | $143.00K |
Operating Income | $-21.14M | $-11.28M | $-8.26M | $-3.58M |
Net Income | $-17.18M | $-11.40M | $-9.15M | $-4.04M |
EPS (Diluted) | $-15.90 | $-13.02 | $-0.74 | $-0.36 |
Total Assets | $15.86M | $25.47M | $25.56M | $24.80M |
Total Liabilities | $9.21M | $19.02M | $19.01M | $16.88M |
Cash & Equivalents | $88.00K | $1.07M | $838.00K | $450.00K |
Free Cash Flow OCF − CapEx | $-8.31M | $-6.80M | $-4.62M | $-2.35M |
Shares Outstanding | 1.74M | 1.65M | 18.86M | 9.27M |
Fundamentals not available for VTAK.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.
Catheter Precision Inc is engaged in the design, manufacture, and sale of medical technologies focused in the field of cardiac electrophysiology, or EP. The company's two primary products include the VIVO System and LockeT. The VIVO System, which is an acronym for View into Ventricular Onset System(VIVO or VIVO System), is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. Its newest product, LockeT, is a suture retention device indicated for wound healing by distributing suture tension over a larger area in the patient in conjunction with a figure of eight suture closure.